| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Rosario Moratalla | Q38329789 |
| P2093 | author name string | Mario Gustavo Murer | |
| P2860 | cites work | Involvement of the extracellular signal-regulated kinase cascade for cocaine-rewarding properties. | Q51423988 |
| Development of dyskinesias in a 5-year trial of ropinirole andL-dopa | Q57088847 | ||
| Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity | Q63256021 | ||
| Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats | Q64779242 | ||
| [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)] | Q64786916 | ||
| Pharmacokinetics and pharmacodynamics of levodopa | Q64958553 | ||
| Is levodopa toxic? | Q67221733 | ||
| Unilateral dopamine denervation blocks corticostriatal LTP | Q73280384 | ||
| D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys | Q73367384 | ||
| Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment | Q73897941 | ||
| Reciprocal regulation of dopamine D1 and D3 receptor function and trafficking by heterodimerization | Q24323514 | ||
| The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies | Q24605294 | ||
| Identification of dopamine D1-D3 receptor heteromers. Indications for a role of synergistic D1-D3 receptor interactions in the striatum | Q24651562 | ||
| BDNF is essential to promote persistence of long-term memory storage | Q24653388 | ||
| Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity | Q28185479 | ||
| Dopamine controls persistence of long-term memory storage | Q28255867 | ||
| cAMP response element-binding protein is required for dopamine-dependent gene expression in the intact but not the dopamine-denervated striatum | Q28366090 | ||
| Sudden appearance of invalidating dyskinesia-dystonia and off fluctuations after the introduction of levodopa in two dopaminomimetic drug naive patients with stage IV Parkinson's disease | Q28369089 | ||
| D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys | Q28371745 | ||
| Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias | Q28376108 | ||
| Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine | Q28376602 | ||
| Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease | Q28377680 | ||
| D2 receptor stimulation, but not D1, restores striatal equilibrium in a rat model of Parkinsonism. | Q45980594 | ||
| Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia | Q46049780 | ||
| L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice | Q46136644 | ||
| Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease. | Q46177753 | ||
| Cabergoline and pramipexole fail to modify already established dyskinesias in an animal model of parkinsonism. | Q46475206 | ||
| Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat. | Q46603970 | ||
| The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease | Q46628501 | ||
| ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice | Q46684571 | ||
| Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum | Q46717751 | ||
| Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA. | Q46750632 | ||
| Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats | Q46778385 | ||
| RGS9-2 negatively modulates L-3,4-dihydroxyphenylalanine-induced dyskinesia in experimental Parkinson's disease. | Q46832204 | ||
| Parsing molecular and behavioral effects of cocaine in mitogen- and stress-activated protein kinase-1-deficient mice. | Q46843660 | ||
| Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat. | Q46859525 | ||
| Critical involvement of cAMP/DARPP-32 and extracellular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia | Q48124096 | ||
| Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease | Q48165678 | ||
| Metabolic interactions between glutamatergic and dopaminergic neurotransmitter systems are mediated through D(1) dopamine receptors. | Q48190449 | ||
| Selective D1 and D2 dopamine agonists differentially alter basal ganglia glucose utilization in rats with unilateral 6-hydroxydopamine substantia nigra lesions | Q48215972 | ||
| D1 but not D5 dopamine receptors are critical for LTP, spatial learning, and LTP-Induced arc and zif268 expression in the hippocampus | Q48223824 | ||
| Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease | Q48243272 | ||
| Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates. | Q48248143 | ||
| Mapping the effects of three dopamine agonists with different dyskinetogenic potential and receptor selectivity using pharmacological functional magnetic resonance imaging | Q48279502 | ||
| Prolonged and extrasynaptic excitatory action of dopamine mediated by D1 receptors in the rat striatum in vivo | Q48654037 | ||
| Atypical and typical neuroleptic treatments induce distinct programs of transcription factor expression in the striatum | Q48892221 | ||
| Dopamine D3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment | Q49113876 | ||
| Levodopa in Parkinsonism: Potentiation of Central Effects with a Peripheral Inhibitor | Q51107835 | ||
| Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. | Q45130529 | ||
| Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia. | Q45281153 | ||
| Modification of Parkinsonism--chronic treatment with L-dopa | Q45300970 | ||
| Inhibition of mTOR signaling in Parkinson's disease prevents L-DOPA-induced dyskinesia. | Q45923687 | ||
| Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson's disease. | Q45928216 | ||
| Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. | Q45972521 | ||
| Spatial learning deficit in dopamine D(1) receptor knockout mice | Q28505043 | ||
| A phosphatase cascade by which rewarding stimuli control nucleosomal response | Q28508656 | ||
| A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia | Q28569068 | ||
| Dopaminergic modulation of the persistence of one-trial hippocampus-dependent memory | Q28582452 | ||
| MAPK cascade signalling and synaptic plasticity | Q29619955 | ||
| Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease | Q30482160 | ||
| Striatal overexpression of DeltaJunD resets L-DOPA-induced dyskinesia in a primate model of Parkinson disease | Q30493275 | ||
| Dichotomous dopaminergic control of striatal synaptic plasticity | Q30493521 | ||
| Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. | Q30594829 | ||
| Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. | Q30783824 | ||
| L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function | Q30837835 | ||
| Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia | Q30988635 | ||
| Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey | Q32061819 | ||
| Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling | Q33428476 | ||
| Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats | Q33628372 | ||
| Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease? | Q33639844 | ||
| Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia | Q33758221 | ||
| Levodopa in Parkinson's disease: neurotoxicity issue laid to rest? | Q33770264 | ||
| Expression of the transcription factor deltaFosB in the brain controls sensitivity to cocaine | Q33875193 | ||
| Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? | Q33890256 | ||
| Neuroimaging of dyskinesia. | Q33890289 | ||
| Clinical pharmacology of levodopa-induced dyskinesia. | Q33890292 | ||
| Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors | Q34093012 | ||
| Maladaptive striatal plasticity in L-DOPA-induced dyskinesia | Q34094008 | ||
| Transition to addiction is associated with a persistent impairment in synaptic plasticity | Q34122596 | ||
| Regulation of gene expression and cocaine reward by CREB and ΔFosB | Q34270890 | ||
| Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. | Q34330176 | ||
| Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys | Q34436772 | ||
| Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. | Q34521936 | ||
| Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial | Q34649706 | ||
| Dopamine-dependent synaptic plasticity in striatum during in vivo development | Q34658296 | ||
| Molecular dissection of dopamine receptor signaling. | Q34669781 | ||
| Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease | Q34770504 | ||
| Levodopa in the treatment of Parkinson's disease: current controversies | Q35889917 | ||
| DeltaFosB: a molecular switch for long-term adaptation in the brain | Q35974744 | ||
| Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa | Q36085612 | ||
| Involvement of hippocampal cAMP/cAMP-dependent protein kinase signaling pathways in a late memory consolidation phase of aversively motivated learning in rats | Q36247860 | ||
| Where do you think you are going? The NMDA-D1 receptor trap | Q36466901 | ||
| Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease | Q36577320 | ||
| Cellular responses to psychomotor stimulant and neuroleptic drugs are abnormal in mice lacking the D1 dopamine receptor | Q37056920 | ||
| In vivo evidence of D3 dopamine receptor sensitization in parkinsonian primates and rodents with l-DOPA-induced dyskinesias | Q37173272 | ||
| Molecular mechanisms of L-DOPA-induced dyskinesia | Q37247578 | ||
| Evaluation of the D3 dopamine receptor selective antagonist PG01037 on L-dopa-dependent abnormal involuntary movements in rats | Q37286573 | ||
| Striatal plasticity and basal ganglia circuit function | Q37336143 | ||
| Personality, addiction, dopamine: insights from Parkinson's disease | Q37403135 | ||
| Dopamine and synaptic plasticity in dorsal striatal circuits controlling action selection | Q37629163 | ||
| Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. | Q37631957 | ||
| Neurotransmitter roles in synaptic modulation, plasticity and learning in the dorsal striatum | Q37680104 | ||
| Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment | Q39398723 | ||
| Is striatal dopaminergic receptor imbalance responsible for levodopa-induced dyskinesia? | Q40980387 | ||
| The effects of L-DOPA on regional cerebral glucose utilization in rats with unilateral lesions of the substantia nigra | Q41451083 | ||
| Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism | Q41976331 | ||
| Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) controls activation of extracellular signal-regulated kinase (ERK) signaling in the striatum and long-term behavioral responses to cocaine. | Q42175909 | ||
| Long-term synaptic depression in the striatum: physiological and pharmacological characterization | Q42453585 | ||
| Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease | Q42466960 | ||
| Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. | Q42492136 | ||
| Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia. | Q42501373 | ||
| Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 | ||
| Network-level changes in expression of inducible Fos-Jun proteins in the striatum during chronic cocaine treatment and withdrawal | Q42521545 | ||
| Chronic alterations in dopaminergic neurotransmission produce a persistent elevation of deltaFosB-like protein(s) in both the rodent and primate striatum | Q42555260 | ||
| Associative learning and CA3-CA1 synaptic plasticity are impaired in D1R null, Drd1a-/- mice and in hippocampal siRNA silenced Drd1a mice. | Q42906391 | ||
| Dopamine and memory: modulation of the persistence of memory for novel hippocampal NMDA receptor-dependent paired associates | Q43174636 | ||
| L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia | Q43202012 | ||
| The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats | Q43280427 | ||
| Knockout of ERK1 MAP kinase enhances synaptic plasticity in the striatum and facilitates striatal-mediated learning and memory | Q44025656 | ||
| D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. | Q44037073 | ||
| Pharmacologically modulated fMRI--cortical responsiveness to levodopa in drug-naive hemiparkinsonian patients | Q44285192 | ||
| Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia | Q44383212 | ||
| Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function | Q44436562 | ||
| Chronic treatment with atypical neuroleptics induces striosomal FosB/DeltaFosB expression in rats | Q44801145 | ||
| Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias. | Q44936180 | ||
| Regulation of histone acetylation during memory formation in the hippocampus. | Q44992481 | ||
| Persistent increase in olfactory type G-protein alpha subunit levels may underlie D1 receptor functional hypersensitivity in Parkinson disease. | Q45007596 | ||
| Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias | Q45030408 | ||
| P921 | main subject | dopamine | Q170304 |
| dyskinesia | Q629444 | ||
| striatum | Q1319792 | ||
| substance abuse | Q3184856 | ||
| long-term memory | Q18601 | ||
| P304 | page(s) | 51 | |
| P577 | publication date | 2011-08-11 | |
| P1433 | published in | Frontiers in Neuroanatomy | Q1893158 |
| P1476 | title | Striatal Signaling in L-DOPA-Induced Dyskinesia: Common Mechanisms with Drug Abuse and Long Term Memory Involving D1 Dopamine Receptor Stimulation | |
| P478 | volume | 5 |
| Q35324207 | A Genetic Mouse Model of Parkinson's Disease Shows Involuntary Movements and Increased Postsynaptic Sensitivity to Apomorphine |
| Q28535290 | A Tet-on system for DRD1-expressing cells |
| Q41967371 | A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson's disease |
| Q36363830 | Activation of Protein Kinases and Phosphatases Coupled to Glutamate Receptors Regulates the Phosphorylation State of DARPP32 at Threonine 75 After Repeated Exposure to Cocaine in the Rat Dorsal Striatum in a Ca2+-Dependent Manner |
| Q27324133 | Are cyclooxygenase-2 and nitric oxide involved in the dyskinesia of Parkinson's disease induced by L-DOPA? |
| Q21131066 | Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's disease |
| Q30650489 | Cell type-specific plasticity of striatal projection neurons in parkinsonism and L-DOPA-induced dyskinesia |
| Q38937893 | Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia |
| Q30836713 | Chemogenetic stimulation of striatal projection neurons modulates responses to Parkinson's disease therapy. |
| Q89626923 | D1-mGlu5 heteromers mediate noncanonical dopamine signaling in Parkinson's disease |
| Q53446566 | Differential Synaptic Remodeling by Dopamine in Direct and Indirect Striatal Projection Neurons in Pitx3-/- Mice, a Genetic Model of Parkinson's Disease. |
| Q35777273 | Differential involvement of Ras-GRF1 and Ras-GRF2 in L-DOPA-induced dyskinesia |
| Q47637177 | Dopamine D3 Receptor Modulates l-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling |
| Q48506998 | Dopamine receptors: homomeric and heteromeric complexes in L-DOPA-induced dyskinesia |
| Q42043545 | Dopamine signaling negatively regulates striatal phosphorylation of Cdk5 at tyrosine 15 in mice |
| Q48280361 | Dopaminergic regulation of olfactory type G-protein α subunit expression in the striatum |
| Q37241754 | Dynamic DNA Methylation Regulates Levodopa-Induced Dyskinesia |
| Q38207680 | Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions |
| Q38834292 | G protein-coupled receptor kinases as regulators of dopamine receptor functions |
| Q58603118 | Genetic enhancement of Ras-ERK pathway does not aggravate L-DOPA-induced dyskinesia in mice but prevents the decrease induced by lovastatin |
| Q48545028 | Gα(olf) mutation allows parsing the role of cAMP-dependent and extracellular signal-regulated kinase-dependent signaling in L-3,4-dihydroxyphenylalanine-induced dyskinesia. |
| Q53642390 | Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice. |
| Q58492844 | Impulsive and compulsive behaviors in Parkinson's disease |
| Q37344222 | L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia |
| Q48843863 | L-DOPA Reverses the Increased Free Amino Acids Tissue Levels Induced by Dopamine Depletion and Rises GABA and Tyrosine in the Striatum. |
| Q48113066 | Levodopa treatment and dendritic spine pathology |
| Q38766091 | Loss and remodeling of striatal dendritic spines in Parkinson's disease: from homeostasis to maladaptive plasticity? |
| Q41860851 | Methamphetamine and Parkinson's disease |
| Q42512289 | Overexpression of GRK6 rescues L-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats. |
| Q39067400 | Potential for targeting dopamine/DARPP-32 signaling in neuropsychiatric and neurodegenerative disorders |
| Q21129423 | Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The Findings, the Debate, and the Therapeutic Implications |
| Q39348706 | Ras-ERK Signaling in Behavior: Old Questions and New Perspectives |
| Q49907939 | Reversing dopaminergic sensitization |
| Q93002959 | Selective Regulation of 5-HT1B Serotonin Receptor Expression in the Striatum by Dopamine Depletion and Repeated L-DOPA Treatment: Relationship to L-DOPA-Induced Dyskinesias |
| Q38931640 | Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice |
| Q42111195 | Striatal signaling: two decades of progress. |
| Q44639804 | Sustained increase of PKA activity in the postcommissural putamen of dyskinetic monkeys. |
| Q42640556 | The nicotine-mediated decline in l-dopa-induced dyskinesias is associated with a decrease in striatal dopamine release |
| Q38100197 | The role of dopamine receptors in the neurotoxicity of methamphetamine. |
| Q28482094 | The role of the subthalamic nucleus in L-DOPA induced dyskinesia in 6-hydroxydopamine lesioned rats |
| Q39279185 | α-Lipoic acid interaction with dopamine D2 receptor-dependent activation of the Akt/GSK-3β signaling pathway induced by antipsychotics: potential relevance for the treatment of schizophrenia |
Search more.